This is the authors' abstract. We don't add key points for this paper.
Spondyloarthritis (SpA) describes a group of interrelated rheumatic disorders comprising ankylosing spondylitis (AS), psoriatic arthritis (PsA), reactive arthritis and inflammatory bowel disease (IBD)-related arthritis. The term axial spondyloarthritis (axSpA) comprises both nonradiographic (nr-axSpA) and radiographic axSpA, also known as AS. Gut inflammation, microbe etiology, IBD, and gastrointestinal symptoms (GI) are considered to be closely associated with SpA.1, 2 Up to 20% of IBD patients, including those with ulcerative colitis and Crohn's disease (CD), develop presentations including peripheral arthritis, anterior uveitis, and sacroiliitis. Conversely, patients with early SpA share 10- to 100-fold higher odds of developing IBD compared to the general population, proven through endoscopic and histological gut inflammation.3 The risk of this may be significantly greater once microscopic bowel inflammation is present at diagnosis.4 Theoretically, the immunological mechanisms of bowel inflammation participate in the onset of joint inflammation in SpA. Histologic evidence demonstrated that both acute and chronic bowel inflammation are intended to acquire more extensive bone marrow edema of the sacroiliac joints and higher risk of progression to AS and developing CD.5 The screening and diagnosis are often made via endoscopy, the invasiveness of the procedure and is not routinely recommended in SpA patients without GI symptoms. Additionally, approximately half of patients with SpA have normal C-reactive protein (CRP) levels, limiting the diagnostic value of this biomarker.6 Therefore, it is crucial to detect reliable diagnostic markers for the screening and evaluating treatment prognosis of SpA. Calprotectin, a calcium-dependent complex of S100A8 (MRP-8)/S100A9 (MRP-14) that belongs to the S-100 protein family, comprising 60% of the cytosol of phagocytic myeloid cells.7 During the early phase of the immune response of inflammation in SpA, it is released from activated monocytes and granulocytes at the synovium in inflammatory arthritis or the intestinal mucosa in IBD. Calprotectin can be found in serum (sCAL) and stool (fecal calprotectin, fCAL), and the elevation of calprotectin was found in several forms of autoimmune inflammation (Figure 1).8 During gut inflammation, calprotectin was abundant in the stool resulting from the migration of inflammatory cells to the mucosa of the GI tract, thus making it more sensitive than serum inflammatory markers such as CRP, erythrocyte sedimentation rate (ESR) and cytokines, including interleukin (IL)-6, IL-17 and tumor necrosis factor (TNF)-α. It is believed that fCAL was more seen in chronic gut inflammation while sCAL was seen in acute type.4 We further describe the clinical importance of both fCAL and sCAL among SpA and the association with gut inflammation. The comparison between both types of calprotectin is summarized in Table 1. axSpA10 AS14 CRP11 ESR11 ASDAS11 BASDAI11 BASFI11 IBD10 BMI > 2515 NSAID4, 11 Anti-TNF11 COVID-1928 axSpA4 AS4 PsA17 Non-specific LBP17 CRP11 ESR11 ASDAS24 BASDAI11 Response to anti-TNF,18 anti-IL17A25 Related to axSpA progression23 Exercise programs26 DMARDs11 Biologics11 COVID-1929 Histological evidence revealed fCAL was linked with acute and chronic inflammation with the latter possessing higher values in patients with SpA.4 The use of fCAL level as a disease activity indicator, screening marker, and prognosis factor for treatment response recently have been well discussed. According to the National Institute for Health and Care Excellence (NICE) guideline reviewed and updated in 2017, the cut-off value of fCAL is 50 mg/g, although several reports with values between 50 and 100 mg/g have been reported as well.4, 9 Regardless of gut inflammation, fCAL was found higher in patients with AS and axSpA, and was linked with worse disease activity and physical function.10 It was found to be significantly correlated with CRP and activity parameters, including Ankylosing Spondylitis Disease Activity Score based on CRP (ASDASCRP), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Patient Global Score, and Bath Ankylosing Spondylitis Functional Index (BASFI) and severity of sacroiliitis.11 However, despite the elevation of fCAL significantly correlates with the disease activity of IBD, Simioni et al10 found no relationship between fCAL, functional and inflammatory parameters of SpA. They hypothesized that gut inflammation may be important in initiating pathophysiology but not maintaining the disease activity of SpA. Furthermore, their study included patients with several types of SpA, not only AS as most studies did. High levels of fCAL in clinically inactive patients with IBD improved its value in early screening of subclinical patients, that is, before the emergence of endoscopic manifestations or clinically significant inflammation.12 A previous meta-analysis revealed a sensitivity of 93% and specificity of 96% of elevated fCAL in the screening of adults with suspected IBD.12 Furthermore, they found a 67% reduction in the number of adults who require endoscopy after fCAL screening. Implementation of fCAL in the initial diagnostic workup of patients without alarm symptoms and low fCAL level demonstrated high accuracy in the exclusion of IBD. Thus, fCAL is able to provide the best sensitivity and specificity for detection of gut inflammation as a single marker in SpA patients.4 Moreover, SpA patients with high fCAL could achieve better response to adalimumab.13 Klingberg et al14 found smoking and elevated fecal calprotectin at baseline were the strongest predictors for high fCAL in AS patients at 5-year follow-up. The downside of this strategy includes the disturbance of the fCAL level by several confounding factors. Approximately 20% of healthy participants, patients using non-steroidal anti-inflammatory drugs (NSAIDs), body mass index (BMI) >25 kg/m2 and even in the groups with coronavirus disease 19 (COVID-19) have statistically significantly higher fCAL levels.15, 16 The users of anti-TNF antibodies, including infliximab, adalimumab, golimumab had significantly lower fCAL compared to patients without therapy.11 Serum calprotectin in SpA patients was also significantly increased in axSpA and AS.4 de Seny et al17 first measured significantly elevated sCAL could be used as a biomarker for patients with PsA and AS. A following study supported their findings by reporting on undifferentiated arthritis patients.18 However, sCAL was not able to discriminate axSpA from non-specific inflammatory back pain. In gut inflammation, elevated sCAL independently predicts the diagnosis of IBD with sensitivity of 69% and specificity of 90%.19 Interestingly, reports found sCAL and fCAL had lack of association.4 Histological evidence acquired from actively inflamed intestinal mucosa demonstrated that sCAL originated only partly from inflamed bowel mucosa in SpA patients with microscopic gut inflammation.20 Thus, sCAL was believed to be predominantly derived from circulating neutrophils not infiltrating in the gut.21 Cypers et al4 proposed a 2-step screening approach using sCAL, CRP and fCAL for risk assessment of bowel inflammation in SpA (area under the receiver operating characteristic curve of 74.4%, Figure 1). SpA patients with both elevated sCAL and CRP showed high risk of developing bowel inflammation, while sCAL or CRP are elevated, in combination with elevated fCAL, showed potentially higher risk of bowel inflammation. However, predictive models have not been replicated in larger studies and require further tests for validation. The counter-reports revealed no difference in sCAL levels in AS and PsA from controls, or even decreased in AS and nr-axSpA.22 The heterogeneity of disease characteristics, including CRP, ESR, BASDAI or BASFI, which were different between studies explained the discordant results. Different enzyme-linked immunosorbent assay (ELISA) platforms and reagents can contribute to alternative measurement of sCAL and fCAL as well.21 Serum calprotectin has been considered an independent marker of radiographic spinal progression and syndesmophyte formation in axSpA.23 The relationship between disease activity and sCAL in SpA patients was found to be strongly connected. Meta-analyses conducted by Ma et al11 concluded that sCAL was significantly related to CRP, ESR and BASDAI in SpA patients. Jarlborg et al24 found an association between sCAL levels and ASDAS score in axSpA patients. Trials conducted by Turina et al18 and Baeten et al25 revealed treatment with anti-TNF and anti-IL-17A agents significantly decreased sCAL levels in axSpA and peripheral SpA. Levitova et al26 reported a significant decrease in sCAL level and disease activity after an intense 6-month-based exercise program in axSpA patients. Furthermore, unlike fCAL, NSAIDs seem to be less effective on sCAL levels, but could be disturbed by disease-modifying anti-rheumatic drugs (DMARDs) like methotrexate and biologics.11 Compared to the general population, patients with rheumatic disease intend to increase risk of hospitalization for COVID-19, admission to the intensive care unit, mechanical ventilation and death.27 Furthermore, GI symptoms were found to affect 28% of patients with COVID-19.28 Current evidence suggested that both fCAL and sCAL were significantly correlated with the severity of COVID-19. However, we found distinctive conclusion regarding the correlation between calprotectin levels and GI symptoms.28 It has been proposed that severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) infects GI tract cells and results in subsequent gut inflammation that produces of IL-6 and increasing intestinal shedding causing abundant fCAL concentration in stools, which potentially deteriorates the course of human IBD.28, 29 Thus, calprotectin may predict the severity and outcome of patient with rheumatic disease who are infected by SARSCoV-2. However, this issue has not been addressed in the literature thus deserves prospective evaluation. In conclusion, both serum and fecal calprotectin are strongly associated with gut inflammation in SpA and could be used as non-invasive screening tools for IBD, proxying disease activity, monitoring gut inflammation and therapeutic response in patients with SpA. However, several confounders have shown effects on calprotectin levels, including anti-inflammatory medications and demographics of patients. Further randomized clinical trials should be performed to achieve stronger evidence for clinical application of calprotectin. James Cheng-Chung Wei is Editor-in-Chief of the journal and coauthor of this article.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Tung et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: